Muscle glutamine may protect the heart by supplying nitrogen for protein glycosylation
During delayed feeding, muscle glutamine may preserve heart protein quality through nitrogen-dependent sugar production. The proposal predicts that blocking this pathway removes protection despite preserved energy and glutathione; protection persisting under that blockade would reject its claimed necessity.
Stage of verification
- Hypothesis published2026-10-06
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Metabolism and energy
Hexosamine biosynthesis
A pathway that produces uridine diphosphate N-acetylglucosamine needed for glycosylation and protein maintenance
Where this hypothesis actsTarget tissue, including the heart, during delayed feeding under an early-fasting mimetic
Hypotheses on this target 1
Inhibition
Activation
Function preservation
Supplementation1
Feedback restoration
Direct measurement
What is proposed
Supplementation
Restore hexosamine flow while reducing dependence on glutamine-derived nitrogen
With whatSmall molecule
HowCombine a short pulse of aldometanib with N-acetylglucosamine to bypass the nitrogen-dependent GFAT1 step, provided N-acetylglucosamine reutilization remains functional
Possible result
Possible preservation of cardiac function and protein quality with less consumption of muscle material
From the recordНовый миметик мог бы сочетать короткий импульс альдометаниба с N-ацетилглюкозамином для обхода азотозависимого этапа GFAT1.
Enzyme
GLS1
An enzyme that uses glutamine and can compete with its use in the hexosamine pathway
Where this hypothesis actsDuring early-fasting mimetic treatment, with alternative fuel available and energy production preserved
Hypotheses on this target 5- Inhibition4
- Activation
Lower level
Higher level
Replacement
Protection from degradation
Cofactor removal
Synthesis suppression- Function preservation
What is proposed
Inhibition
Partially suppress GLS1 while preserving energy production
With whatNot stated in the record
HowNot stated in the record
Possible result
Possible preservation or enhancement of protection with lower muscle costs
From the recordЧастичное подавление GLS1 сохраняет или усиливает защиту при доступном альтернативном топливе.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Making the body behave as though food is scarce could protect the heart while consuming material supplied by muscle. The unexpected move is to propose that glutamine, a small molecule carrying nitrogen, helps maintain heart proteins through sugar attachments rather than mainly serving as fuel. This is a hypothesis generated by the pipeline, not a measured result; it suggests pairing aldometanib, the proposed drug signal for early fasting, with a replacement supply for making those attachments.
- Under the proposed early-fasting signal, muscle supplies glutamine to the heart.
- Glutamine–fructose-6-phosphate amidotransferase 1 (GFAT1), an enzyme that transfers glutamine nitrogen into a sugar-building reaction, directs that nitrogen into the hexosamine pathway.
- The pathway produces uridine diphosphate N-acetylglucosamine, a sugar donor used for protein glycosylation.
- The resulting sugar attachments are proposed to maintain protein quality and preserve heart function when feeding is delayed.
- Glutaminase 1 (GLS1), an enzyme that breaks down glutamine, is proposed to compete for the same supply and increase demand on muscle.
- Partially reducing GLS1 while maintaining energy supply is predicted to preserve or improve protection, whereas stopping glutamine delivery is predicted to remove protection.
- Adding N-acetylglucosamine, a sugar proposed as a replacement input, alongside a short aldometanib pulse is predicted to bypass the GFAT1-dependent step if the sugar-reuse route works.
- Reducing protein damage while consuming less muscle material is proposed to contribute to longer life.
A workshop receives material that can either be burned for heat or used to maintain its equipment. This proposal says the crucial benefit comes from maintenance, so providing a replacement maintenance supply could spare the original material.
Where the picture breaks: Glutamine's uses are connected chemical reactions, not separate bins. The picture does not establish that a replacement reaches the heart, restores the required sugar attachments or reduces muscle expenditure.
- Master questionstep 01 of 04
Reproducing useful effects of normal bodily processes might yield new ways to extend life.
Rests on: The stated goal is to propose substances, combinations or other interventions that reproduce such effects and explain their possible connection to longer life.
Stated in the chain - Goal pillarstep 02 of 04
A signal that imitates a bodily process should match the resources available and the body's actual need for that process.
Rests on: The search for useful imitation is narrowed to whether the response is appropriate and affordable for the body.
AssumptionThe pillar takes resource availability and physiological need as governing conditions for a useful intervention; the master question does not supply that criterion.
- Gap questionstep 03 of 04
An intervention that imitates early fasting might preserve energy in one tissue by drawing glutamine from muscle, making protection dependent on that supply when feeding is delayed.
Rests on: The preceding resource requirement motivates examining whether a benefit in one tissue carries a cost elsewhere and whether interrupting that exchange removes the benefit.
Stated in the chain - Hypothesisstep 04 of 04
Muscle glutamine is proposed to protect heart protein quality by supplying nitrogen for glycosylation, the attachment of sugars to proteins. Reducing competing glutamine use or providing a replacement sugar is proposed to preserve protection while reducing muscle expenditure.S2S4
Rests on: The gap supplies the proposed muscle-to-heart exchange. iScience (2023) describes glutamine nitrogen entering the hexosamine pathway, a sequence of reactions that makes supplies for sugar attachments, and Diabetologia (1997) describes the machinery for attaching one such sugar to proteins; neither establishes that this exchange protects the heart during delayed feeding or extends life.
Supported by literature
What is carried, and what is not. Screened sources directly describe the biochemical steps underlying two links in the ordered mechanism: glutamine nitrogen entering sugar synthesis and sugar attachment to proteins, as described in iScience (2023) and Diabetologia (1997); neither source establishes the proposed heart protection. No supplied source establishes the sequence end to end, and iScience (2021) reports that reducing GFAT1 did not reduce the measured protein sugar attachment in a drug-induced heart-cell enlargement model, limiting any assumption that GFAT1 necessarily controls that process across heart conditions.
Where the reasoning is carried by something unstated · 1
- Goal pillar. The pillar takes resource availability and physiological need as governing conditions for a useful intervention; the master question does not supply that criterion.
How a result here could mislead · 3
- More nitrogen-15, a distinguishable form of nitrogen used as a tracer, appearing in heart sugar products could be read as proof that muscle supplies the protective material. Label incorporation alone establishes neither its muscle origin nor its necessity for protection. What closes it: The test must establish the origin of the delivered glutamine and measure the amount passing through the pathway alongside label incorporation. Dependence of heart protection on that route must be tested separately.
- Loss of protection after reducing GFAT1 could be attributed to impaired protein sugar attachment even if that attachment remains unchanged. In iScience (2021), reducing GFAT1 left the measured attachment unchanged during drug-induced heart-cell enlargement; that result does not settle the delayed-feeding setting but makes the assumed link unsafe. What closes it: The proposed test must verify reduced pathway activity and the relevant protein sugar attachments in the tested heart system. Adenosine triphosphate (ATP), the cell's immediate energy-carrying molecule, and glutathione, a molecule involved in protection against damaging oxidation, must remain preserved as the prediction requires, with accompanying stress responses assessed.
- Restored protection after N-acetylglucosamine could be credited to bypassing GFAT1 even if another response caused the improvement. Conversely, failure to restore protection could reflect failure to use the supplied sugar. What closes it: The test must confirm that supplied sugar enters the proposed reuse route and restores pathway activity. The specified blockade of sugar reuse must remove the restoration of protection, and accompanying stress responses must be measured.
What would make this wrong. The central claim would fail if heart protection persisted after verified suppression of the proposed GFAT1-dependent nitrogen flow and its protein sugar attachments, while energy and glutathione remained preserved. That observation would contradict the claimed necessity of this branch, even if muscle glutamine still protected the heart through another route.
What it would change. If the mechanism held, reproducing fasting's useful effects would require accounting for nitrogen used in protein maintenance as well as energy supply. The proposed combination would offer a way to seek heart protection with less demand on muscle, although reduced muscle expenditure would itself need measurement. Even a successful mechanism test would not establish longer life: the supplied test description specifies no species, duration or lifespan measurement.
Sources read · 7
A novel variant of glutamine: fructose-6-phosphate amidotransferase-1 (GFAT1) mRNA is selectively expressed in striated muscle. · Diabetes · 2001
“GFAT1Alt is the predominant GFAT1 mRNA in mouse hindlimb muscle, is weakly expressed in the heart, and is undetectable in the brain, liver, kidney, lung, intestine, spleen, and 3T3-L1 adipocytes.”
Does not settle: Остаются открытыми передача амидного азота из мышечного глутамина в сердце, влияние этого процесса на гликозилирование и качество сердечных белков, зависимость сохранения функции сердца при задержке питания, роль GLS1, действие альдометаниба и N-ацетилглюкозамина, расход мышечного материала и продление жизни.
Splicing regulation of GFPT1 muscle-specific isoform and its roles in glucose metabolisms and neuromuscular junction. · iScience · 2023
“Glutamine:fructose-6-phosphate transaminase (GFPT/GFAT) is the first-step and rate-limiting enzyme of HBP, which catalyzes the conversion of fructose-6-phosphate (F-6-P) to glucosamine-6-phosphate (GlcN-6-P), as well as glutamine to glutamate in parallel, via an amidotransaminase reaction”
Does not settle: The source does not establish that muscle glutamine protects the heart during delayed feeding, that this protection depends on GFPT1-mediated nitrogen transfer, that GLS1 competes for glutamine or increases muscle loss, that GLS1 inhibition is protective, that aldometanib combined with N-acetylglucosamine bypasses GFPT1, or that any such intervention reduces protein damage or extends lifespan.
Molecular characterization, chromosomal location, alternative splicing and polymorphism of porcine GFAT1 gene. · Molecular biology reports · 2010
“Glutamine: fructose-6-phosphate amidotransferase (GFAT) is the rate-limiting enzyme of the hexosamine synthesis pathway, which plays important roles in insulin resistance and glucose toxicity.”
Does not settle: The source does not establish that muscle glutamine supplies nitrogen to protect cardiac protein quality, that cardiac preservation during delayed feeding depends on GFAT1, that GLS1 competes for glutamine or increases muscle loss, or that aldometanib combined with N-acetylglucosamine protects the heart or extends lifespan.
UDP-N-acetylglucosamine transferase and glutamine: fructose 6-phosphate amidotransferase activities in insulin-sensitive tissues. · Diabetologia · 1997
“Glutamine:fructose 6-phosphate amidotransferase (GFA) is rate-limiting for hexosamine biosynthesis, while a UDP-GlcNAc beta-N-acetylglucosaminyltransferase (O-GlcNAc transferase) catalyses final O-linked attachment of GlcNAc to serine and threonine residues on intracellular proteins.”
Does not settle: The source does not establish that muscle-derived glutamine supplies the heart, preserves cardiac function during delayed feeding, maintains protein quality, or reduces muscle loss. It does not examine fasting mimetics, aldomethanib, GLS1 inhibition, N-acetylglucosamine supplementation, protein damage, energetics, or lifespan.
GFAT2 mediates cardiac hypertrophy through HBP-O-GlcNAcylation-Akt pathway. · iScience · 2021
“GFAT1 knockdown did not affect ISO-induced protein O-GlcNAcylation in spite of its anti-hypertro-phic effect (Figures S10A and S10B).”
Does not settle: Источник не исследует миметик раннего голодания, поступление глутамина из мышц, конкуренцию со стороны GLS1, сохранение функции сердца при задержке питания, сочетание альдометаниба с N-ацетилглюкозамином, расход мышечной ткани или продолжительность жизни. Результаты получены в модели гипертрофии кардиомиоцитов, вызванной изопротеренолом, где ключевая роль отведена GFAT2.
The hexosamine biosynthetic pathway induces gene promoter activity of acetyl-CoA carboxylase beta. · Biochemical and biophysical research communications · 2014
“The administration of l-glutamine (HBP substrate) dose-dependently increased, while HBP inhibitors attenuated pPIIβ-1317 activity. Co-transfections with dominant-negative GFAT constructs diminished pPIIβ-1317 activity.”
Does not settle: Остаются открытыми происхождение глутамина из мышц, передача амидного азота, синтез уридиндифосфат-N-ацетилглюкозамина, гликозилирование и качество белков, функция сердца при задержке питания, роль GLS1, действие альдометаниба и N-ацетилглюкозамина, расход мышечной ткани и продление жизни. Исследование охватывает активность промотора ACCβ2 в клетках H9c2, а не функцию сердца в организме.
O-GlcNAcylation, novel post-translational modification linking myocardial metabolism and cardiomyocyte circadian clock. · The Journal of biological chemistry · 2011
“These time-of-day-dependent variations appear to be mediated by clock-dependent regulation of O-GlcNAc transferase and O-GlcNAcase protein levels, glucose metabolism/uptake, and glutamine synthesis in an NAD-independent manner.”
Does not settle: Источник описывает суточную регуляцию O-GlcNAc-модификации в сердце мышей. Он не устанавливает роль мышечного глутамина, голодания или его миметика, GFAT1, GLS1, передачи амидного азота, расхода мышечной ткани, сохранения функции сердца, применения N-ацетилглюкозамина либо продления жизни.
The gap this hypothesis explains
Does copying early fasting preserve tissue energy using muscle fuel, with protection during delayed feeding requiring this transfer?
Original wording · exactly as the pipeline generated it
Может ли миметик раннего голодания сохранять энергию целевой ткани ценой расходования мышечного глутамина, и устраняет ли разрыв этого обмена защитный эффект при задержке питания?
What this question is asking
The question concerns whether a treatment that imitates the body's early response to going without food protects one tissue by drawing on fuel supplied by muscle. That fuel is glutamine, an amino acid that muscles produce and release and that other tissues can use. It asks whether the treatment preserves energy in the receiving tissue while feeding is delayed, compared with the same conditions without treatment. It then asks whether blocking the proposed glutamine transfer removes that protection compared with leaving the transfer intact. The treatment, receiving tissue, duration of the feeding delay and measures of energy and protection are unspecified; the proposed exchange is a possibility being questioned, rather than an established fact.
- Early fasting
- The initial period of going without food. The question gives no duration or specific bodily response that defines this period.
- Fasting mimetic
- A treatment intended to imitate some response to going without food. This names a proposed kind of intervention, not a specified substance or a demonstrated reproduction of every effect of fasting.
- Glutamine
- An amino acid, one of the substances used to make proteins, that also has other roles in the body. Here it is the proposed muscle-supplied fuel; S1 describes both its fuel role and its role in supporting production of genetic-information molecules.
- Skeletal muscle
- Muscle used to move and support the body. In this question it is the proposed source of glutamine supplied to another tissue.
- Receiving tissue
- The part of the body proposed to benefit from muscle-supplied glutamine. The question does not identify it, so the gut and kidney findings cannot automatically stand for the intended tissue.
- Tissue energy preservation
- Maintaining a tissue's available energy or ability to meet its energy needs. The question does not specify how this would be measured, and repair alone is not a stated measurement of it.
- Glutamine transfer
- The proposed passage of glutamine from muscle to a receiving tissue for use there. Increased release from muscle establishes only part of that proposed connection.
- Delayed feeding
- Food or nutritional supply arriving later than it otherwise would. Neither the length of the delay nor the feeding conditions are supplied.
- Protection
- A reduction in tissue harm or preservation of tissue function. The question does not define the outcome that would count as protection or establish that it is identical to maintaining energy.
- Ketone bodies
- A class of molecules the body can use as fuel during fasting. S2 examines elevated concentrations in relation to amino acid release from muscles of fasted birds.
- Alanine and glutamate
- Two amino acids involved in the muscle response described by S2. That source reports a shift away from alanine release and attributes increased glutamine production to greater glutamate availability.
- Glucocorticoids
- A class of hormones involved in responses to stress and regulation of how the body uses its resources. S3 describes them promoting protein breakdown, which increases muscle glutamine release.
- Protein breakdown
- The dismantling of proteins into smaller components, including amino acids. S3 places this process between the hormone response and increased glutamine supply for gut repair.
- Gut lining and immune cells
- The gut lining is the layer of cells facing the inside of the digestive tract; immune cells participate in the body's defenses. These are reported recipients or users of glutamine in S1 and S3.
- Dexamethasone
- A drug in the glucocorticoid class. S4 includes treatment with it among the settings associated with increased muscle glutamine release in sheep; the supplied material does not establish it as the fasting mimetic asked about.
- Energy is preserved, and blocking transfer removes protection Under this outcome, the treatment's benefit would depend on the muscle-to-tissue glutamine transfer under the conditions examined. Protection during delayed feeding would therefore require continued access to that supply, although a harmful cost to muscle would remain a separate question.
- Energy is preserved, but protection survives blocked transfer If the transfer were successfully blocked and protection remained, that transfer would not be necessary for the observed protection. Muscle glutamine release could accompany the treatment without explaining why the receiving tissue remains protected.
- The treatment does not preserve tissue energy The proposed energy benefit would not occur under the conditions examined. Even if muscle released more glutamine, that release would not establish the protective exchange described in the question.
Muscle-produced glutamine can supply fuel to cells lining internal surfaces and to immune cells, providing a reported starting point for the proposed connection between tissues [S1]. If a treatment preserves another tissue's energy by increasing its use of this supply, that benefit could depend on a continuing contribution from muscle. Increased glutamine release alone, however, would not establish either a damaging cost to muscle or protection of the receiving tissue. Mistaking release for demonstrated protection would overstate the evidence, while assuming protection is independent of muscle supply could conceal the dependency the question asks about.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
При действии миметика раннего голодания мышечный глутамин поддерживает качество белков целевой ткани через передачу амидного азота в гексозаминовый путь. Глутамин-фруктозо-6-фосфат-амидотрансфераза GFAT1 обеспечивает образование уридиндифосфат-N-ацетилглюкозамина, необходимого для гликозилирования и поддержания белкового обмена. Сохранение функции сердца при задержке питания зависит от этой ветви. Усиленная GLS1 конкурирует за глутамин и способна увеличивать мышечные затраты. Поэтому ослабление GLS1 при сохранённой энергетике может улучшить защиту, тогда как прекращение поступления самого глутамина её разрушит. Новый миметик мог бы сочетать короткий импульс альдометаниба с N-ацетилглюкозамином для обхода азотозависимого этапа GFAT1. Потенциальное продление жизни связано с уменьшением белкового повреждения при меньшем расходе мышечного материала. Стабилизируемое свойство: SPV_4.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
Миметик увеличивает включение амидного 15N глутамина в гексозамины целевой ткани. Частичное подавление GFAT1 устраняет защиту при сохранённых АТФ и глутатионе. N-ацетилглюкозамин восстанавливает защиту и уменьшает потребность в поступающем глутамине только при работоспособном пути его повторного использования. Частичное подавление GLS1 сохраняет или усиливает защиту при доступном альтернативном топливе. Блокада использования N-ацетилглюкозамина отменяет специфическое восстановление.
Would tell it apart from at least one rival. The prediction specifies observable directional changes and conditional loss, preservation, or restoration of protection. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Амидно-меченый глутамин позволяет отделять азотный вклад от углеродного окисления. Доступны измерения гексозаминов, гликозилирования и белковых агрегатов. Разделение механизмов требует подтвердить восстановление гексозаминового потока и оценить сопутствующие изменения стрессового ответа.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
Миметик увеличивает включение амидного 15N глутамина в гексозамины целевой ткани. Частичное подавление GFAT1 устраняет защиту при сохранённых АТФ и глутатионе. N-ацетилглюкозамин восстанавливает защиту и уменьшает потребность в поступающем глутамине только при работоспособном пути его повторного использования. Частичное подавление GLS1 сохраняет или усиливает защиту при доступном альтернативном топливе. Блокада использования N-ацетилглюкозамина отменяет специфическое восстановление.
- What would separate them
Early-fasting mimetics may protect the heart by burning glutamine supplied by muscle predicts: У старых мышей при задержке питания миметик увеличивает чистый выход глутамина из задней конечности и его углеродный вклад в окислительный обмен сердца. Избирательное подавление сердечной GLS1 снижает образование АТФ раньше появления повреждений и устраняет защиту. В изолированном сердце альтернативное окисляемое топливо восстанавливает защиту при сохранённой блокаде GLS1, если экспериментально подтверждено восстановление энергетического потока. При повторных циклах величина мышечной потери связана с интегральным экспортом и недостаточным восстановительным синтезом.
- Rival 02 of 04What would separate them
Energy spending in the glutamine–glutamate cycle may protect the heart during fasting mimicry predicts: При неизменном поступлении глутамина и сохранённой GLS1 частичное подавление GLUL в кардиомиоцитах уменьшает встречные потоки синтеза и гидролиза глутамина, повышает отношение АТФ к аденозиндифосфату, но увеличивает восстановленность дыхательной цепи и устраняет защиту миметика. В клеточной модели регулируемая дополнительная АТФазная нагрузка восстанавливает защиту при сопоставимых аммиаке, глутатионе и гликозилировании. Простое энергетическое восполнение при отсутствии такого оборота защиты не возвращает.
- Rival 03 of 04What would separate them
Connected mitochondria may protect ageing heart cells when muscle glutamine supply falls predicts: При сопоставимых массе митохондрий, максимальной дыхательной мощности и доступности топлива зависимость функции сердца от ослабления GLS1 имеет порог, положение которого меняется при изменении связности сети. Увеличение связности сохраняет защиту после ослабления GLS1 при низком поступлении мышечного глутамина. Фрагментация отменяет этот эффект даже при восстановленных глутатионе и гексозаминовом обмене. Порог должен воспроизводиться при двух независимых способах изменения связности.
- Rival 04 of 04What would separate them
Muscle glutamine may protect the heart by supporting glutathione-dependent lipid peroxide removal predicts: После подавления сердечной GLS1 липидные перекиси растут раньше падения АТФ. В клеточной модели липроксстатин-1 либо подтверждённое восстановление внутриклеточного глутатиона возвращает защиту миметика при сохраняющемся снижении окисления глутамина. Альтернативное топливо, восстановившее энергетический поток, сохраняет недостаточную защиту. После обхода окислительного повреждения частичное подавление GLUL не должно воспроизводить обязательную потерю защиты, предсказанную another hypothesis of the same gap.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.